TetraKit Technologies - Pipeline

Download as PDF

Compound/Candidate	Radionuclide	Type	Indication	Phase
18F-DualFAPi DualFAPi-7	18F	PET	FAP Expressing Tumors	Pre-clinical
Radionuclide: 18F Type: PET Indication: FAP Expressing Tumors Phase: Pre-clinical Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by IHI and the European Union
123I-DualFAPi DualFAPi-5	123I	γ	FAP Expressing Tumors	Pre-clinical
Radionuclide: 123I Type: γ Indication: FAP Expressing Tumors Phase: Pre-clinical Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union
131I-DualFAPi DualFAPi-5	131I	β⁻	FAP Expressing Tumors	Pre-clinical
Radionuclide: 131I Type: β⁻ Indication: FAP Expressing Tumors Phase: Pre-clinical Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by the European Union
211At-DualFAPi DualFAPi-5	211At	α	FAP Expressing Tumors	Late discovery
Radionuclide: 211At Type: α Indication: FAP Expressing Tumors Phase: Late discovery Candidate: TetraKit Description: Target: Fibroblast Activation Protein (FAP) Partner/co-funding: Co-funded by IHI and the European Union
18F-FlutraProst PSMA-TBD	18F	PET	Prostate cancer	First-In-Human
Radionuclide: 18F Type: PET Indication: Prostate cancer Phase: First-In-Human Candidate: TetraKit Description: Target: PSMA Partner/co-funding: Co-funded by Eurostars
18F-FlutraTate OCT-TBD	18F	PET	NETs	Late discovery
Radionuclide: 18F Type: PET Indication: NETs Phase: Late discovery Candidate: TetraKit Description: Target: SSTR/ Octreotate Partner/co-funding: Co-funded by IHI and the European Union
211At-AstraTate OCT-TBD	211At	α	NETs	Discovery
Radionuclide: 211At Type: α Indication: NETs Phase: Discovery Candidate: TetraKit Description: Target: SSTR/Octreotate Partner/co-funding: Co-funded by Innovation Fund Denmark

Download as PDF

Compound/Candidate	Radionuclide	Type	Indication	Phase
18F-FlutaHexin TVX-01	18F	PET	Pancreatic cancer	Pre-clinical
Radionuclide: 18F Type: PET Indication: Pancreatic cancer Phase: Pre-clinical Candidate: TetraKit Description: Target: αvβ6 integrin Partner/co-funding: TRIMT
3BP (211At) 3BP-TBD	211At	α	Undisclosed	Late discovery
Radionuclide: 211At Type: α Indication: Undisclosed Phase: Late discovery Candidate: TetraKit Description: Target: Undisclosed Partner/co-funding: 3B Pharmaceuticals
AmbiTag for Pretargeting AmbiTag	131I/211At	β⁻ / α	Epithelial-derived cancers	Late discovery
Radionuclide: 131I/211At Type: β⁻ / α Indication: Epithelial-derived cancers Phase: Late discovery Candidate: TetraKit Description: Target: CD44v6 Partner/co-funding: Co-funded by Eurostars. Partners includes Pre-TT and Akiram Therapeutics

TetraKit Technologies ApS
Ole Maaløes Vej 3, DK-2200 Copenhagen Denmark

About:

About Company Partnerships Funding

Science:

Platform Pipeline

Other:

News Team Contact Careers

Legal:

Connect with us:

© 2022 TetraKit Technologies. All rights reserved